What we know about the role of corticosteroids in psychiatric disorders; evidence from animal and clinical studies

J Psychiatr Res. 2022 Nov:155:363-370. doi: 10.1016/j.jpsychires.2022.09.032. Epub 2022 Sep 21.

Abstract

Corticosteroids, often known as steroids, are anti-inflammatory medicine prescribed for various conditions. There is accumulating evidence of immune dysregulation in major psychiatric disorders. Significant changes in concentrations of inflammatory biomarkers (i.e., IL-6 and TNF-a) have been previously reported in individuals with schizophrenia, autistic individuals, and depressive patients. Thus, systemic corticosteroids can be used as an adjuvant treatment to reduce inflammation in major psychiatric disorders. However, despite their well-known potent anti-inflammatory and immunosuppressant properties, this treatment is often associated with increased severity of several psychiatric symptoms and relapse. This article reviews the available literature on psychiatric and cognitive changes during corticosteroid therapy. Specifically, we will provide data on the good and the bad of corticosteroid therapy in autism, schizophrenia, mood disorders, and PTSD. This review will summarize the vital role of corticosteroid therapy in social and cognitive behavior.

Keywords: Autism; Corticosteroid; Glucocorticoid receptors; Inflammation; Major psychiatric disorders; Mood disorders; Schizophrenia.

Publication types

  • Review

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Animals
  • Biomarkers
  • Immunosuppressive Agents
  • Interleukin-6*
  • Mental Disorders* / drug therapy

Substances

  • Adrenal Cortex Hormones
  • Biomarkers
  • Immunosuppressive Agents
  • Interleukin-6